Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 5

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 5
---
 that show the highest likelihood of being successful in the treatment of
a variety of human diseases, test those strains and then work to produce those strains in a medicinal form for the treatment of disease.
The research plan will be conducted using the following steps: Extraction, Purification, Sequencing. Annotation, and Cloning (micro-propagation).

5

Extraction: The extraction
of genomic DNA from cannabis is a complex process of cell lysis and DNA recovery. Sangre has evaluated, updated, and validated new methods
for DNA recovery.

Purification: Using
next generation purification chemistries, the DNA is cleaned and concentrated for downstream applications.

Sequencing: The Cannabis
DNA is sequenced using both the Illumina MiSeq and MinIon instruments.

Annotation: The genomic
data is assembled and annotated using proprietary bioinformatic systems and the data provided to the Sangre AgroTech genetic breeders
and cellular cloners.

Cloning: Through
this process, new, high-value cannabis strains are developed.

The objectives of the research
plan are as follows:

Technical Objective 1:
Using two next generation sequencing platforms and proprietary bioinformatics programs, we will sequence five cultivars of Cannabis, and
generate fully annotated genomic data.

Technical Objective 2:
Using the selected cultivars, backcross and forward hybridization studies will be performed to produce a new generation of stock.
The progeny of these crosses will be grown, genetically finger-printed, and introduced to the market under patent protection. Up-selection
and cultivation of cultivars for quality assurance.

Technical Objective 3:
Genotypic and phenotypic measurements of the offspring will be performed using Next Generation Sequence Analysis, Genotyping, and
Phenotyping analysis. Product focus groups will evaluate new cultivars. Patent protection will be initiated for new cultivars which meet
product development criteria.

Technical Objective 4: Utilize
gene-driven breeding of up-selected cultivars to initiate the generation of “designer” cultivars for clinical research.

Technical Objective 5:
Market placement of selected, genetically enhanced cultivars for the medicinal and bio-pharma markets.

Where We Are in the Research
Plan

As noted above, phase one
of our planned pilot study “Cannabis Genomic Study” includes “extraction technologies”. On April 20, 2017, we,
in connection with Industrial Metagenomics, initiated the genomic study by extracting DNA from seven cannabis strains in Tucson, Arizona.
Sangre followed the